$HELP News

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health - Slideshow

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Helus Pharma Announces Completion of Legal Name Change

Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data

Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026

Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change

Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions

TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62

Cybin (HELP) Names New CEO, Is The Stock Still Cheap?

Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?

Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions

Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million

Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?